Acelrx pharmaceuticals reports second quarter 2022 financial results and provides corporate update

Advanced niyad™ supply chain development with a focus on obtaining an emergency use authorization in 2023 $0.6 million net revenue in q2 2022; fifth consecutive quarter of commercial (ex-dod) sales volume growth for dsuvia, with a 133% increase compared to q2 2021; on track for eu launch of dzuveo in the third quarter projected annual savings of $9 million beginning in june 2022 from realigned cost structure $27.9 million in cash and short-term investments as of june 30, 2022 $84.1 million gain on extinguishment of debt due to termination of royalty monetization webcast and conference call to be held today at 4:30 p.m. edt hayward, calif.
ACRX Ratings Summary
ACRX Quant Ranking